Point72 Asset Management
RIGL icon

Point72 Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Point72 Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75
Closed -$991 – 2693
2023
Q1 		$991 Buy
+75
New +$1.19K ﹤0.01% 2125
2021
Q2 		– Sell
-116,090
Closed -$3.97M – 1139
2021
Q1 		$3.97M Buy
+116,090
New +$4.6M 0.02% 618

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's RIGL Position: Q2 2023 in Review

Point72 Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2023, closing a stake of 75 shares — an estimated $991 sold.

Point72 Asset Management first reported a position in RIGL in Q1 2021 and held it in 2 quarters. The position peaked at $3.97M in Q1 2021. 118 funds tracked by Wall St. Rank hold RIGL as of Q2 2023.

  • Point72 Asset Management reported no remaining Rigel Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Asset Management sold 75 Rigel Pharmaceuticals shares in Q2 2023, an estimated $991.
  • Point72 Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Point72 Asset Management's Rigel Pharmaceuticals position peaked at $3.97M in Q1 2021.
  • 118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.